These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12678855)

  • 1. Matrix metalloproteinases: a therapeutic target in cardiovascular disease.
    Sierevogel MJ; Pasterkamp G; de Kleijn DP; Strauss BH
    Curr Pharm Des; 2003; 9(13):1033-40. PubMed ID: 12678855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
    Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
    Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and atherosclerosis.
    Watanabe N; Ikeda U
    Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
    George SJ
    Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases and coronary artery diseases.
    Ikeda U; Shimada K
    Clin Cardiol; 2003 Feb; 26(2):55-9. PubMed ID: 12625594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases.
    Zitka O; Kukacka J; Krizkova S; Huska D; Adam V; Masarik M; Prusa R; Kizek R
    Curr Med Chem; 2010; 17(31):3751-68. PubMed ID: 20846107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
    Liu J; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases: their biological functions and clinical implications.
    Hijova E
    Bratisl Lek Listy; 2005; 106(3):127-32. PubMed ID: 16026148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
    Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
    Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
    Li YY; Feldman AM
    Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.
    Galis ZS; Khatri JJ
    Circ Res; 2002 Feb; 90(3):251-62. PubMed ID: 11861412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metalloproteinase inhibitors: biological actions and therapeutic opportunities.
    Baker AH; Edwards DR; Murphy G
    J Cell Sci; 2002 Oct; 115(Pt 19):3719-27. PubMed ID: 12235282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
    Rouis M
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):541-8. PubMed ID: 16503874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metalloproteinases in development and progression of vascular disease.
    Lijnen HR
    Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):275-81. PubMed ID: 15692229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.
    Johnson JL
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):265-82. PubMed ID: 17338671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases in vascular disease--a potential therapeutic target?
    Lim CS; Shalhoub J; Gohel MS; Shepherd AC; Davies AH
    Curr Vasc Pharmacol; 2010 Jan; 8(1):75-85. PubMed ID: 19485936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.